Meeting
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
Authors
Shipra Gandhi
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Shipra Gandhi , Arya Mariam Roy , Hans Minderman , Spencer Rosario , Elizabeth A. Repasky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT05741164
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS1141)
DOI
10.1200/JCO.2024.42.16_suppl.TPS1141
Abstract #
TPS1141
Poster Bd #
108b
Abstract Disclosures
Similar Posters
First Author: Jose Luis Iglesias
Poster
2017 ASCO Annual Meeting
Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.
First Author: Maryann J. Kwa
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer.
First Author: Alice Ho
Poster
2024 ASCO Annual Meeting
Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.
First Author: Benjamin Adam Weinberg